HUE13746964T2
(hu)
|
2012-02-06 |
2020-01-28 |
Inhibrx Inc |
CD47 antitestek és alkalmazási eljárásaik
|
DK2931752T3
(da)
*
|
2012-12-17 |
2019-11-18 |
Trillium Therapeutics Inc |
Behandling af cd47+ sygdomsceller med sirp-alpha-fc-fusioner
|
CA2903773A1
(en)
*
|
2013-03-15 |
2014-09-25 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods for achieving therapeutically effective doses of anti-cd47 agents
|
CA2910466A1
(en)
|
2013-04-29 |
2014-11-06 |
The Board Of Trustees Of The Leland Stanford Junior University |
Use of anti-cd47 agents to enhance immunization
|
EP3046627B1
(en)
*
|
2013-09-18 |
2019-10-23 |
The Board of Trustees of the Leland Stanford Junior University |
Modulation of efferocytosis pathways for treatment of atherosclerotic disease
|
US10040862B2
(en)
|
2014-04-18 |
2018-08-07 |
The Board Of Trustees Of The Leland Stanford Junior University |
Humanized and chimeric monoclonal antibodies to CD99
|
TWI759810B
(zh)
*
|
2014-08-08 |
2022-04-01 |
美商Alx腫瘤技術股份有限公司 |
信號調節蛋白α(signal-regulatory proteinα, SIRP-α)變體構築物及其用途
|
WO2016023001A1
(en)
*
|
2014-08-08 |
2016-02-11 |
The Board Of Trustees Of The Leland Stanford Junior University |
Multispecific high affinity pd-1 agents and methods of use
|
US9546206B2
(en)
|
2014-08-08 |
2017-01-17 |
The Board Of Trustees Of The Leland Stanford Junior University |
High affinity PD-1 agents and methods of use
|
US10087257B2
(en)
|
2014-08-08 |
2018-10-02 |
The Board Of Trustees Of The Leland Stanford Junior University |
SIRP alpha-antibody fusion proteins
|
ES2751915T5
(es)
|
2014-08-15 |
2022-12-23 |
Merck Patent Gmbh |
Proteínas de fusión de inmunoglobulina con SIRP alfa
|
WO2016033201A1
(en)
|
2014-08-26 |
2016-03-03 |
The Board Of Trustees Of The Leland Stanford Junior University |
Engraftment of stem cells with a combination of an agent that targets stem cells and modulation of immunoregulatory signaling
|
WO2016044021A1
(en)
|
2014-09-15 |
2016-03-24 |
The Board Of Trustees Of The Leland Stanford Junior University |
Targeting aneurysm disease by modulating phagocytosis pathways
|
EP3012271A1
(en)
|
2014-10-24 |
2016-04-27 |
Effimune |
Method and compositions for inducing differentiation of myeloid derived suppressor cell to treat cancer and infectious diseases
|
EP3209769B1
(en)
|
2014-10-24 |
2020-08-05 |
The Board of Trustees of the Leland Stanford Junior University |
Compositions and methods for inducing phagocytosis of mhc class i positive cells and countering anti-cd47/sirpa resistance
|
SG11201704058TA
(en)
*
|
2014-11-18 |
2017-06-29 |
Janssen Pharmaceutica Nv |
Cd47 antibodies, methods, and uses
|
WO2016109415A1
(en)
*
|
2014-12-30 |
2016-07-07 |
Celgene Corporation |
Anti-cd47 antibodies and uses thereof
|
EP3261671B1
(en)
|
2015-02-27 |
2020-10-21 |
The Board of Trustees of the Leland Stanford Junior University |
Combination therapy for treatment of atherosclerosis
|
CN106146670B
(zh)
*
|
2015-04-24 |
2019-01-15 |
宜明昂科生物医药技术(上海)有限公司 |
一种新的重组双功能融合蛋白及其制备和应用
|
US10358472B2
(en)
|
2015-05-06 |
2019-07-23 |
The Board Of Trustees Of The Leland Stanford Junior University |
High affinity CD47 analogs
|
CN114425077A
(zh)
*
|
2015-05-18 |
2022-05-03 |
起源生物医药公司 |
Sirp多肽组合物和使用方法
|
BR102016018074A2
(pt)
|
2015-08-07 |
2021-11-16 |
ALX Oncology Inc. |
Construção variante de sirp-alfa, seu método de preparação e seus usos, molécula de ácido nucleico, vetor, célula hospedeira, e composição farmacêutica
|
CN108350048B
(zh)
*
|
2015-08-07 |
2024-02-09 |
Alx肿瘤生物技术公司 |
具有SIRP-α结构域或其变体的构建体
|
AU2016310348B2
(en)
|
2015-08-26 |
2023-01-05 |
The Board Of Trustees Of The Leland Stanford Junior University |
Enhanced depletion of targeted cells with CD47 blockade and an immune costimulatory agonist
|
CA3005911A1
(en)
*
|
2015-12-11 |
2017-06-15 |
The Board Of Trustees Of The Leland Stanford Junior University |
Treatment of cancer with dual targeting of cd47 and egfr
|
CN114716552B
(zh)
|
2016-01-11 |
2024-05-24 |
四十七公司 |
人源化、小鼠或嵌合抗cd47单克隆抗体
|
UA126658C2
(uk)
|
2016-04-14 |
2023-01-11 |
Осе Іммьюнотерапьютікс |
НОВІ АНТИТІЛА ДО SIRPa ТА ВАРІАНТИ ЇХ ТЕРАПЕВТИЧНОГО ЗАСТОСУВАННЯ
|
AU2017250809B2
(en)
|
2016-04-15 |
2024-02-29 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods for determining and achieving therapeutically effective doses of anti-CD47 agents in treatment of cancer
|
US11649284B2
(en)
|
2016-04-18 |
2023-05-16 |
Baylor College Of Medicine |
Cancer gene therapy targeting CD47
|
WO2017190148A1
(en)
|
2016-04-29 |
2017-11-02 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods and compositions for the prevention and treatment of surgical adhesions
|
US11560433B2
(en)
|
2016-05-27 |
2023-01-24 |
Albert Einstein College Of Medicine |
Methods of treatment by targeting VCAM1 and MAEA
|
US10148939B2
(en)
|
2016-07-19 |
2018-12-04 |
Gopro, Inc. |
Mapping of spherical image data into rectangular faces for transport and decoding across networks
|
US10995152B2
(en)
|
2016-10-26 |
2021-05-04 |
The Board Of Trustees Of The Leland Stanford Junior University |
Modified immunoglobulin hinge regions to reduce hemagglutination
|
CA3042581A1
(en)
|
2016-11-03 |
2018-05-11 |
Trillium Therapeutics Inc. |
Enhancement of cd47 blockade therapy by proteasome inhibitors
|
US11779631B2
(en)
|
2016-11-03 |
2023-10-10 |
Pfizer Inc. |
CD47 blockade therapy by HDAC inhibitors
|
KR102129067B1
(ko)
*
|
2016-12-29 |
2020-07-08 |
한국과학기술연구원 |
신규 엑소좀 계열 항암제
|
WO2018127916A1
(en)
|
2017-01-05 |
2018-07-12 |
Kahr Medical Ltd. |
A pd1-cd70 fusion protein and methods of use thereof
|
ES2916217T3
(es)
|
2017-01-05 |
2022-06-29 |
Kahr Medical Ltd |
Una proteína de fusión SIRP1 ALPHA-41BBL y métodos de uso de la misma
|
HRP20230937T1
(hr)
|
2017-01-05 |
2023-11-24 |
Kahr Medical Ltd. |
Pd1-41bbl fuzijski protein i metode korištenja istog
|
AU2018205276A1
(en)
|
2017-01-06 |
2019-07-18 |
Synlogic Operating Company, Inc. |
Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells
|
EP3573629A4
(en)
|
2017-01-30 |
2020-10-14 |
The Board of Trustees of the Leland Stanford Junior University |
NON-GENOTOXIC CONDITIONING REGIME FOR STEM CELL TRANSPLANTATION
|
US11286301B2
(en)
*
|
2017-02-28 |
2022-03-29 |
The Board Of Trustees Of The Leland Stanford Junior University |
Antifibrotic activity of CD47 blockade
|
WO2018165015A1
(en)
|
2017-03-09 |
2018-09-13 |
The Board Of Trustees Of The Leland Stanford Junior University |
Treatment of pediatric brain tumors with targeting of cd47 pathway
|
AU2018290248A1
(en)
|
2017-06-21 |
2019-11-28 |
Forty Seven, Inc. |
Dosing parameters for CD47 targeting therapies to hematologic malignancies
|
US20200149053A1
(en)
|
2017-07-12 |
2020-05-14 |
Synlogic Operating Company, Inc. |
Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells
|
US11401329B2
(en)
|
2017-08-02 |
2022-08-02 |
Phanes Therapeutics, Inc. |
Anti-CD47 antibodies and uses thereof
|
CN111051350B
(zh)
*
|
2017-09-07 |
2022-11-01 |
苏州丁孚靶点生物技术有限公司 |
包含信号调节蛋白α的免疫缀合物
|
WO2019061012A1
(zh)
*
|
2017-09-26 |
2019-04-04 |
南京凯地生物科技有限公司 |
靶向cd47的特异性嵌合抗原受体t细胞的制备及其应用
|
US11713356B2
(en)
|
2017-10-13 |
2023-08-01 |
Ose Immunotherapeutics |
Modified bifunctional anti-human signal regulatory protein alpha (SIRPa) antibody and method of use thereof for treating cancer
|
PL3697817T3
(pl)
|
2017-10-18 |
2023-01-23 |
Forty Seven, Inc. |
Terapia nowotworu złośliwego jajnika w oparciu o środek anty-cd47
|
US11771764B2
(en)
|
2017-11-06 |
2023-10-03 |
Pfizer Inc. |
CD47 blockade with radiation therapy
|
US11180552B2
(en)
*
|
2017-12-01 |
2021-11-23 |
Seagen Inc. |
CD47 antibodies and uses thereof for treating cancer
|
EP3722312A4
(en)
*
|
2017-12-08 |
2021-07-21 |
Hanx Biopharmaceutics, Inc |
ANTI-PD-1 / CD47 BIS SPECIFIC ANTIBODY AND APPLICATION THEREOF
|
CN109971716B
(zh)
*
|
2017-12-28 |
2023-08-01 |
上海细胞治疗研究院 |
自分泌cd47抗体的egfr特异性car-t细胞及其用途
|
WO2019157432A1
(en)
|
2018-02-12 |
2019-08-15 |
Forty Seven, Inc. |
Anti-cancer regimen using anti-cd47 and anti-cd20 antibodies
|
CN108484774B
(zh)
*
|
2018-03-09 |
2021-11-05 |
上海高菲生物科技有限公司 |
一种SIRPα融合蛋白及其制备方法和用途
|
EP3765080A4
(en)
*
|
2018-03-13 |
2022-03-16 |
Trillium Therapeutics Inc. |
IMPROVEMENTS IN THERAPY FOR CD47 BLOCKADE BY EGFR ANTIBODIES
|
AU2019233577A1
(en)
|
2018-03-13 |
2020-09-03 |
Ose Immunotherapeutics |
Use of anti-human SIRPa v1 antibodies and method for producing anti-SIRPa v1 antibodies
|
CN108872569A
(zh)
*
|
2018-06-19 |
2018-11-23 |
浠思(上海)生物技术有限公司 |
利用HTRF一步法筛选CD47/SIRP alpha阻断剂的方法
|
KR102129522B1
(ko)
*
|
2018-07-26 |
2020-07-02 |
한국과학기술연구원 |
암세포 특이적 항암 단백질-형광 복합체 및 이를 포함하는 암의 진단 및 영상화용 조성물
|
EP3843772A2
(en)
|
2018-08-31 |
2021-07-07 |
ALX Oncology Inc. |
Decoy polypeptides
|
WO2020047651A1
(en)
|
2018-09-04 |
2020-03-12 |
Trillium Therapeutics Inc. |
Cd47 blockade with parp inhibition for disease treatment
|
CN109306017B
(zh)
*
|
2018-10-12 |
2021-02-09 |
倍而达药业(苏州)有限公司 |
一种基于SIRP-αD1突变体制备的重组蛋白及应用
|
JPWO2020095922A1
(ja)
*
|
2018-11-07 |
2021-09-30 |
第一三共株式会社 |
ペプチドの血中動態改善方法
|
US20220023348A1
(en)
|
2018-11-28 |
2022-01-27 |
Forty Seven, Inc. |
Genetically modified hspcs resistant to ablation regime
|
CA3122914A1
(en)
|
2018-12-21 |
2020-06-25 |
Ose Immunotherapeutics |
Bifunctional anti-pd-1/sirp.alpha. molecule
|
BR112021024003A2
(pt)
|
2019-05-31 |
2022-04-19 |
Alx Oncology Inc |
Métodos de tratamento de câncer com fusão sirp alfa-fc em combinação com um inibidor de checkpoint imunológico
|
EP3980747A1
(en)
|
2019-06-07 |
2022-04-13 |
ALX Oncology Inc. |
Methods and reagents for reducing the interference of drugs that bind cd47 in serological assays
|
WO2020257196A1
(en)
*
|
2019-06-17 |
2020-12-24 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods of treating infections by blocking pathogen mimics of cd47
|
WO2021011544A1
(en)
|
2019-07-16 |
2021-01-21 |
Gilead Sciences, Inc. |
Hiv vaccines and methods of making and using
|
JP7371243B2
(ja)
|
2019-10-18 |
2023-10-30 |
フォーティ セブン, インコーポレイテッド |
骨髄異形成症候群及び急性骨髄性白血病を治療するための併用療法
|
CN114599392A
(zh)
|
2019-10-31 |
2022-06-07 |
四十七公司 |
基于抗cd47和抗cd20的血癌治疗
|
MX2022006078A
(es)
|
2019-11-27 |
2022-08-02 |
Alx Oncology Inc |
Terapias de combinacion para el tratamiento del cancer.
|
MX2022007930A
(es)
|
2019-12-24 |
2022-08-08 |
Carna Biosciences Inc |
Compuestos moduladores de diacilglicerol quinasa.
|
WO2021163064A2
(en)
|
2020-02-14 |
2021-08-19 |
Jounce Therapeutics, Inc. |
Antibodies and fusion proteins that bind to ccr8 and uses thereof
|
JP2023528341A
(ja)
|
2020-06-01 |
2023-07-04 |
エーエルエックス オンコロジー インコーポレイテッド |
低メチル化剤を含むがんを治療するための併用療法
|
WO2022010806A1
(en)
|
2020-07-06 |
2022-01-13 |
ALX Oncology Inc. |
Methods for reducing the interference of drugs that bind therapeutic targets expressed on blood cells in serological assays
|
KR102557016B1
(ko)
*
|
2020-09-22 |
2023-07-20 |
비피진 주식회사 |
암 치료를 위한 cd47 바인더 및 리포좀 복합체
|
TWI815194B
(zh)
|
2020-10-22 |
2023-09-11 |
美商基利科學股份有限公司 |
介白素2-Fc融合蛋白及使用方法
|
WO2022120286A1
(en)
|
2020-12-06 |
2022-06-09 |
ALX Oncology Inc. |
Multimers for reducing the interference of drugs that bind cd47 in serological assays
|
CA3212351A1
(en)
|
2021-03-12 |
2022-09-15 |
Mendus B.V. |
Methods of vaccination and use of cd47 blockade
|
TW202302145A
(zh)
|
2021-04-14 |
2023-01-16 |
美商基利科學股份有限公司 |
CD47/SIRPα結合及NEDD8活化酶E1調節次單元之共抑制以用於治療癌症
|
JP2024515211A
(ja)
|
2021-04-27 |
2024-04-05 |
ファイザー・インク |
Dhfr阻害剤を用いたcd47遮断療法の増強
|
US20220363779A1
(en)
|
2021-05-13 |
2022-11-17 |
ALX Oncology Inc. |
Combination therapies for treating cancer
|
EP4359413A1
(en)
|
2021-06-23 |
2024-05-01 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
CA3222439A1
(en)
|
2021-06-23 |
2022-12-29 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
AU2022299051A1
(en)
|
2021-06-23 |
2023-12-07 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
WO2022271677A1
(en)
|
2021-06-23 |
2022-12-29 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
WO2023003331A1
(en)
*
|
2021-07-19 |
2023-01-26 |
Yuhan Corporation |
Sirp-alpha variants and use thereof
|
AU2022375782A1
(en)
|
2021-10-28 |
2024-05-02 |
Gilead Sciences, Inc. |
Pyridizin-3(2h)-one derivatives
|
WO2023073580A1
(en)
|
2021-10-29 |
2023-05-04 |
Pfizer Inc. |
Enhancement of cd47 blockade with taxanes for cd47+ cancer therapy
|
AU2022376954A1
(en)
|
2021-10-29 |
2024-05-02 |
Gilead Sciences, Inc. |
Cd73 compounds
|
TW202330631A
(zh)
*
|
2021-11-01 |
2023-08-01 |
大陸商江蘇先聲藥業有限公司 |
SIRPa突變體及其應用
|
WO2023079438A1
(en)
|
2021-11-08 |
2023-05-11 |
Pfizer Inc. |
Enhancement of cd47 blockade therapy with anti-vegf agents
|
WO2023107956A1
(en)
|
2021-12-08 |
2023-06-15 |
Dragonfly Therapeutics, Inc. |
Proteins binding nkg2d, cd16 and 5t4
|
WO2023107954A1
(en)
|
2021-12-08 |
2023-06-15 |
Dragonfly Therapeutics, Inc. |
Antibodies targeting 5t4 and uses thereof
|
AU2022421675A1
(en)
*
|
2021-12-21 |
2024-05-02 |
Fbd Biologics Limited |
ENGINEERED SIRPα VARIANTS AND METHODS OF USE THEREOF
|
AU2022417491A1
(en)
|
2021-12-22 |
2024-05-23 |
Gilead Sciences, Inc. |
Ikaros zinc finger family degraders and uses thereof
|
WO2023122581A2
(en)
|
2021-12-22 |
2023-06-29 |
Gilead Sciences, Inc. |
Ikaros zinc finger family degraders and uses thereof
|
WO2023121890A1
(en)
*
|
2021-12-23 |
2023-06-29 |
Fbd Biologics Limited |
Cd47/4-1bb-targeting protein complex and methods of use thereof
|
AU2022435471A1
(en)
*
|
2022-01-18 |
2024-05-30 |
Fbd Biologics Limited |
Cd47/pd-l1-targeting protein complex and methods of use thereof
|
TW202340168A
(zh)
|
2022-01-28 |
2023-10-16 |
美商基利科學股份有限公司 |
Parp7抑制劑
|
WO2023154578A1
(en)
|
2022-02-14 |
2023-08-17 |
Sana Biotechnology, Inc. |
Methods of treating patients exhibiting a prior failed therapy with hypoimmunogenic cells
|
WO2023178181A1
(en)
|
2022-03-17 |
2023-09-21 |
Gilead Sciences, Inc. |
Ikaros zinc finger family degraders and uses thereof
|
WO2023183313A1
(en)
|
2022-03-22 |
2023-09-28 |
Sana Biotechnology, Inc. |
Engineering cells with a transgene in b2m or ciita locus and associated compositions and methods
|
WO2023183890A1
(en)
*
|
2022-03-24 |
2023-09-28 |
Bitterroot Bio, Inc. |
Multivalent sirp-alpha fusion polypeptides
|
WO2023183892A1
(en)
|
2022-03-24 |
2023-09-28 |
Bitterroot Bio, Inc. |
Sirp-alpha fusion polypeptides with modified fc domains
|
US20230355796A1
(en)
|
2022-03-24 |
2023-11-09 |
Gilead Sciences, Inc. |
Combination therapy for treating trop-2 expressing cancers
|
TW202345901A
(zh)
|
2022-04-05 |
2023-12-01 |
美商基利科學股份有限公司 |
用於治療結腸直腸癌之組合療法
|
TW202400138A
(zh)
|
2022-04-21 |
2024-01-01 |
美商基利科學股份有限公司 |
Kras g12d調節化合物
|
WO2023228044A1
(en)
|
2022-05-25 |
2023-11-30 |
Pfizer Inc. |
Dosing regimens of sirp alpha fusion proteins for treatment of cancer
|
WO2023235754A1
(en)
|
2022-06-01 |
2023-12-07 |
ALX Oncology Inc. |
Combination therapies for treating urothelial carcinoma
|
WO2024006929A1
(en)
|
2022-07-01 |
2024-01-04 |
Gilead Sciences, Inc. |
Cd73 compounds
|
WO2024015741A1
(en)
|
2022-07-12 |
2024-01-18 |
Gilead Sciences, Inc. |
Hiv immunogenic polypeptides and vaccines and uses thereof
|
WO2024040151A1
(en)
|
2022-08-18 |
2024-02-22 |
Pfizer Inc. |
Sirp alpha fusion protein and anti-cd38 antibody combination therapies
|
WO2024064668A1
(en)
|
2022-09-21 |
2024-03-28 |
Gilead Sciences, Inc. |
FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY
|